Emergent BioSolutions (EBS) Other Non-Current Assets (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Other Non-Current Assets of $13.0 million for Q1 2026, up 251.35% year-over-year from $3.7 million in Q1 2025, and down 8.45% quarter-over-quarter from $14.2 million in Q4 2025.
Emergent BioSolutions (EBS) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $13.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 251.35% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (up 251.35% YoY), while the FY2025 annual figure was $14.2 million, up 132.79% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $13.0 million, down from $14.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $57.1 million in Q1 2022, with the low at $500000.0 in Q1 2024.
- The 4-year median for Other Non-Current Assets is $9.0 million (2024), against an average of $17.5 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets plunged 60.08% in 2022, then surged 640.0% in 2025.
- Emergent BioSolutions' Other Non-Current Assets stood at $40.8 million in 2022, then sank by 85.05% to $6.1 million in 2024, then jumped by 132.79% to $14.2 million in 2025, then dropped by 8.45% to $13.0 million in 2026.
- Business Quant data shows EBS's Other Non-Current Assets at $13.0 million in Q1 2026, $14.2 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.49 Bn | 43.53 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.69 Bn | 40.04 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.30 Bn | 30.62 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.97 Bn | 19.31 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.97 Bn | 18.08 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.95 Bn | 11.42 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 13.00 Mn |
| 10 | Emergent BioSolutions | 253.36 Mn | 112.46 Mn | 137.20 Mn | 11.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.00 Mn |
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 14.20 Mn |
| Sep 30, 2025 | 11.60 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Mar 31, 2025 | 3.70 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 30, 2024 | 6.50 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 500,000.00 |
| Sep 30, 2022 | 40.80 Mn |
| Jun 30, 2022 | 51.30 Mn |
| Mar 31, 2022 | 57.10 Mn |
| Dec 31, 2021 | 58.20 Mn |
| Sep 30, 2021 | 102.20 Mn |
| Jun 30, 2021 | 109.90 Mn |
| Mar 31, 2021 | 111.40 Mn |
| Dec 31, 2020 | 113.40 Mn |
| Sep 30, 2020 | 106.40 Mn |
| Jun 30, 2020 | 29.00 Mn |